June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
The new once-daily multidose preservative-free 0.6% bilastine eye drop formulation containing sodium hyaluronate preserves ocular surface integrity and tear film homeostasis in a comparative in vivo study.
Author Affiliations & Notes
  • Tatiana M. Suarez-Cortes
    Research, Development and Innovation Department, Faes Farma Vizcaya, Vizcaya, Bilbao, Spain
  • Eider Arana
    Research, Development and Innovation Department, Faes Farma Vizcaya, Vizcaya, Bilbao, Spain
  • Ana Gonzalo
    Research, Development and Innovation Department, Faes Farma Vizcaya, Vizcaya, Bilbao, Spain
  • Arturo Zazpe
    Research, Development and Innovation Department, Faes Farma Vizcaya, Vizcaya, Bilbao, Spain
  • Ines Torrens
    Research, Development and Innovation Department, Faes Farma Vizcaya, Vizcaya, Bilbao, Spain
  • Noelia Andollo
    Department of Cell Biology and Histology, Universidad del Pais Vasco Facultad de Medicina y Enfermeria, Lejona, Vizcaya, Spain
    Instituto de Investigacion Sanitaria Biocruces Bizkaia, Barakaldo, Spain
  • Javier Soria
    Data Analytics Department, Ibermatica, Vizcaya, Derio, Spain
  • Gonzalo Hernández
    Research, Development and Innovation Department, Faes Farma Vizcaya, Vizcaya, Bilbao, Spain
  • Footnotes
    Commercial Relationships   Tatiana Suarez-Cortes FAES FARMA, Code E (Employment); Eider Arana FAES FARMA, Code E (Employment); Ana Gonzalo FAES FARMA, Code E (Employment); Arturo Zazpe FAES FARMA, Code E (Employment); Ines Torrens FAES FARMA, Code E (Employment); Noelia Andollo None; Javier Soria FAES FARMA, Code C (Consultant/Contractor); Gonzalo Hernández FAES FARMA, Code E (Employment)
  • Footnotes
    Support  Basque Country Government (Economic Development and Infrastructures Department), HAZITEK program. Grant number ZE 2019 00004
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 209. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tatiana M. Suarez-Cortes, Eider Arana, Ana Gonzalo, Arturo Zazpe, Ines Torrens, Noelia Andollo, Javier Soria, Gonzalo Hernández; The new once-daily multidose preservative-free 0.6% bilastine eye drop formulation containing sodium hyaluronate preserves ocular surface integrity and tear film homeostasis in a comparative in vivo study.. Invest. Ophthalmol. Vis. Sci. 2023;64(8):209.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Notwithstanding the large number of studies evaluating the efficacy of topical antihistamines, mast cell stabilizers or dual action agents for allergic conjunctivitis treatment, research of their impact on the ocular surface is needed. The aim of this work was to perform an in vivo evaluation of the effect of repeated treatment with the new preservative-free 0.6% bilastine eye drops containing sodium hyaluronate on the ocular surface and tear film homeostasis in rabbits.

Methods : A prospective single-masked study was performed in 21 New Zealand rabbits with once-daily treatment administration during 60 consecutive days. The animals were randomized in three groups (N=7 each): Control (Saline solution), multidose preservative-free bilastine (6 mg/mL) and multidose olopatadine hydrochloride (7.76 mg/mL). The rabbits were evaluated before (day 0) and after (15, 30, 45 and 60 days) the instillation of the ophthalmic formulations. The effect on eye irritation, corneal damage, tear volume (Schirmer test), Tear break-up time (TBUT) and goblet cells functionality was evaluated. The expression of 10 inflammatory biomarkers was also measured in tears using Multiplex Rabbit Cytokine Array. Statistical analyses were conducted using non-parametric Kruskal-Wallis, variance analysis (ANOVA) models with repeated measures, between others (p<0.05 was considered significant).

Results : Bilastine eye drops did not affect any of the ocular surface parameters evaluated and was comparable to the control group. Olopatadine eye drops induced a significant reduction of TBUT at 15, 30, 45 and 60 days compared to day 0 (p<0.05), and a significant decrease of the tear volume at 15 days after treatment (p<0.01), but it did not affect corneal staining, goblet cell density or mucin cloud height. The tear proteins profile of rabbits treated with bilastine eye drops was similar to control, whereas olopatadine eye drops induced a significant increase of protein inflammatory biomarkers IL-17α, IL-1α, IL-8 and MMP9 (p<0.001).

Conclusions : The new preservative-free once-daily multidose formulation of bilastine 0.6% eye drops containing sodium hyaluronate exhibits an enhanced capacity to protect the ocular surface integrity and the tear film homeostasis after repeated administration than multidose 0.7% olopatadine eye drops.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×